图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm Therapeutics Inc.(KPTI)$ CORRESP [Cover] - Correspondence Filed: 2018-02-13 AccNo: 0001193125-18-041454 Size: 5 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ CORRESP [Cover] - Correspondence Filed: 2018-02-13 AccNo: 0001193125-18-042087 Size: 6 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ CORRESP [Cover] - Correspondence Filed: 2018-02-13 AccNo: 0001193125-18-041454 Size: 5 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-03-15 AccNo: 0001193125-18-083102 Size: 49 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-03-15 AccNo: 0001193125-18-083087 Size: 113 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-03-12,Director,Mirza Mansoor Raza ,卖出,2500普通股, $17.01
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-03-12,Director,Mirza Mansoor Raza ,期权,2500普通股, $0.26
$Karyopharm Therapeutics Inc.(KPTI)$ 美东时间 2018-03-15 盘前 披露财报,预期EPS -0.66 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-03-07,总裁 & CSO,Shacham Sharon ,卖出,10000普通股, $16.15
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-03-07,总裁 & CSO,Shacham Sharon ,期权,10000普通股, $0.26